Hi Sav,
I am always happy to give an opinion (and remember it is just that).
Essentially, what you say is correct. They can patent for an application and the method of extraction. I am not absolutely sure about the combination, but under some scenario's it could be done. All of this will afford some protection, but not the ideal protection that patenting CGNC would.
My main concern with SLA is that the information available to me does not convince me that BioA or any of the other bioeffectives are anymore than vitamin supplements. This comes back to the type and amount of data they have released. In my eyes, it just isn't enough. For example, if SLA did a study on cirrhosis patients and showed that Ropren cured/halted/slowed the disease in humans relative to a placebo or other preferably FDA approved treatment, I wouldn't have a problem with them. Instead all they talk about is "hepatoprotective" changes, without actually demonstrating that the patient is any better off.
I have other issues, but that is the main one.
Cheers,
Bill
- Forums
- ASX - By Stock
- SLA
- solagran announcement out
solagran announcement out, page-26
-
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online